Levels of soluble Fas/APO-1 in patients with Behcet's disease.

Authors: Hamzaoui, K  Hamzaoui, A  Zakraoui, L  Chabbou, A 
Citation: Hamzaoui K, etal., Mediators Inflamm. 1998;7(2):111-4.
Pubmed: (View Article at PubMed) PMID:9836498
DOI: Full-text: DOI:10.1080/09629359891261

The aim of this study was to quantify soluble Fas/APO-1 (sFas/APO-1) protein in the serum of patients with Behcet's disease (BD) in active and inactive stages, compared with patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Increased serum sFas/APO-1 levels were observed in active BD, compared with inactive BD, RA patients and SLE patients. Increased serum sFas/APO-1 levels were correlated with the presence of neurologic manifestations or pulmonary involvement in active BD. In conclusion, increased levels of sFas/APO-1 occurred frequently and exclusively in active BD patients. Preliminary evidence suggested that elevated levels of sFas/APO-1 are associated with the clinical stage and clinical manifestations in BD.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 8662438
Created: 2014-06-24
Species: All species
Last Modified: 2014-06-24
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.